Windtree Therapeutics Q4 2023 GAAP EPS $(0.95) Misses $(0.94) Estimate
Portfolio Pulse from Benzinga Newsdesk
Windtree Therapeutics (NASDAQ:WINT) reported a Q4 2023 GAAP EPS loss of $(0.95), missing the consensus estimate of $(0.94) by 1.06%.
April 17, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Windtree Therapeutics reported a Q4 2023 GAAP EPS loss of $(0.95), slightly missing the consensus estimate by 1.06%.
Missing the consensus estimate, even by a small margin, can negatively impact investor sentiment and potentially lead to a short-term decrease in stock price. The close miss indicates a slight underperformance compared to market expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100